TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02787928
Drug: Intrathecal hydromorphone
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal hydromorphone will be administered in an up/down dosage fashion. A successful dose will be defined as a patient not requiring additional narcotic pain medication outside of the standard VCU order set, which includes PRN oxycodone 5 and 10 mg every 4 hours and a one time PRN 1 mg hydromorphone IV. Failure of a dose will be if patient requires additional narcotic pain medication outside of these parameters
Study: NCT00297219
Drug: Low dialysate calcium
Normalized name: low-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mmol/L dialysate calcium
Study: NCT00297219
Drug: high dialysate calcium
Normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.75 mmol/L dialysate calcium
Study: NCT00364702
Drug: methylphenidate
Normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00087139
Drug: ixabepilone
Normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT03066115
Drug: L-NMMA
Normalized name: L-NMMA
DrugBank: Tilarginine (DB11815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: See arm description.
Study: NCT02910817
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The metformin-treated group received metformin (1000 mg per day) with the start of controlled ovarian stimulation (COH) until the day of the pregnancy check.
Study: NCT00380939
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00976495
Drug: Dapagliflozin
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablets, Oral, 10 mg, once daily, 12 weeks
Study: NCT00298324
Drug: Myfortic
Normalized name: Myfortic
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1440mg twice daily
Study: NCT00976495
Drug: Hydrochlorothiazide
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets, Oral, 25 mg, once daily, 12 weeks
Study: NCT00298324
Drug: Prednisone and Cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone and Cyclosporine given according to protocol. The drugs are tapered according to patient response
Study: NCT02272816
Drug: Carboplatin AUC-10
Normalized name: carboplatin 10 MG/ML
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin AUC-10 according to the Calvert formula \[10 x (glomerular filtration rate (ml/min) + 25)\]mg given in 5% glucose over 1 hour every 21 days for 3 or 4 cycles.
Study: NCT03217669
Drug: Epacadostat
Normalized name: epacadostat
DrugBank: Epacadostat (DB11717)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epacadostat tablet: 100mg or 300mg
Study: NCT03217669
Drug: sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus tablet: 1mg, 2mg, 3mg, or 6mg
Study: NCT04405921
Drug: Hydroxychloroquine 200 Mg Oral Tablet
Normalized name: hydroxychloroquine 200 mg oral tablet
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: orally or via gastric tube
Study: NCT00000936
Drug: hOKT3
Normalized name: hOKT3 gamma1(Ala-Ala)
DrugBank: Teplizumab (DB06606)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered both during and after transplantation in IV form. Dosage determined by individual weight and given for a maximum of 14 days.
Study: NCT00000936
Drug: Oral Cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally as either sandimmune or neoral at a dose determined by weight. Patients 6 years of age and older begin at a dose of 15 mg/kg/day and patients under 6 years of age receive 500 mg/m2/day, for the duration of the study.
Study: NCT00000936
Drug: IV Cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously (IV) both during and after transplantation at a dosage determined by individual age.
Study: NCT04073953
Drug: RPQ
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The study will compare the individual enantiomers of Primaquine -R-(-)-PQ, S-(+)-PQ, and Placebo.
Study: NCT04073953
Drug: SPQ
Normalized name: Sulfapyridine
DrugBank: Sulfapyridine (DB00891)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The study will compare the individual enantiomers of Primaquine -R-(-)-PQ, S-(+)-PQ, and Placebo.
Study: NCT01136876
Drug: Iopamidol
Normalized name: Iopamidol
DrugBank: Iopamidol (DB08947)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iopamidol 370, one time administration for percutaneous coronary intervention
Study: NCT01136876
Drug: Iodixanol-320
Normalized name: Iodixanol
DrugBank: Iodixanol (DB01249)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iodixanol-320 single administration for percutaneous coronary intervention procedure
Study: NCT01122641
Drug: Vildagliptin
Normalized name: Vildagliptin
DrugBank: Vildagliptin (DB04876)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Vildagliptin 50mg bid
Study: NCT02682953
Drug: Neupogen
Normalized name: Neupogen
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pharmacological agents often used for stem cell mobilization will be utilized in this study.
Study: NCT00332917
Drug: Pardoprunox
Normalized name: Pardoprunox
DrugBank: Pardoprunox (DB12061)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-42 mg
Study: NCT03359889
Drug: PraxbindTM
Normalized name: Praxbind
DrugBank: Idarucizumab (DB09264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug
Study: NCT02682953
Drug: Plerixafor
Normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmacological agents often used for stem cell mobilization will be utilized in this study.
Study: NCT03667482
Drug: Cabozantinib
Normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cabozantinib will be initiated at 40 mg PO daily, with subsequent 20 mg or 40 mg doses as tolerated per the study design.
Study: NCT03667482
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab will be administered at 500 mg/m\^2 intravenously every other week on Days 1 and 15 of each cycle, with a window of up to 3 days before the scheduled date. In an effort to prevent a hypersensitivity reaction, it is recommended that all patients pre-medications, hydration, and anti-emetics will be given according to institutional guidelines and/or per treating physician discretion.
Study: NCT02517918
Drug: Sirolimus combined with CP, MT and ZA
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cyclophosphamide, Methotrexate and Sirolimus will be administrated orally. Zoledronic Acid will be administrated by infusion (IV).~Trial based on a dose escalating study design assessing two dose levels of sirolimus when prescribed in combination with metronomic cyclophosphamide (CP), methotrexate (MT) and zoledronic acid (ZA) followed by an expansion cohort once the MTD is established.
Study: NCT00738023
Drug: Rosiglitazone
Normalized name: Rosiglitazone
DrugBank: Rosiglitazone (DB00412)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diabetic subjects will be receive rosiglitazone for 6 weeks
Study: NCT00738023
Drug: Intralipid 20%
Normalized name: Intralipid 20% Fat Emulsion for Injection
DrugBank: Soybean oil (DB09422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralipid 20% at 40ml/hr intravenously for 48 hours
Study: NCT00344994
Drug: pramipexole
Normalized name: Pramipexole
DrugBank: Pramipexole (DB00413)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PO, 0.25mg, 0.50mg, or 0.75mg QHS
Study: NCT01592773
Drug: Memantine Hydrochloride (HCl)
Normalized name: Memantine Hydrochloride
DrugBank: Memantine (DB01043)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: During the 6-week double-blind dosing titration/maintenance period, Memantine extended-release 3-mg and 6-mg capsules; oral administration. Dosing was once daily.~During open-label treatment: Memantine extended-release 3mg capsules; oral administration. The maximum target dosage was identified during the prior studies for each patient. Dosing was once daily.
Study: NCT00531310
Drug: Reduced Intensity Conditioning, Busulfan and Fludarabine
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Busulfan and Fludarabine
Study: NCT01293123
Drug: Raltegravir
Normalized name: Raltegravir
DrugBank: Raltegravir (DB06817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: raltegravir 400 mg PO twice daily
Study: NCT01293123
Drug: Efavirenz
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: efavirenz 600 mg PO once daily
Study: NCT00533546
Drug: Activated Protein C
Normalized name: Activated protein C
DrugBank: Drotrecogin alfa (DB00055)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous APC (10, 15, 22, 33, 50, and 75 mcg/kg) administered to patients with acute ischemic stroke within 0 - 9 hours of symptom onset
Study: NCT03024151
Drug: Synthroid
Normalized name: Synthroid
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: T4 mono replacement
Study: NCT00343161
Drug: esomeprazole
Normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00343161
Drug: Gelusil-Lac (Aluminum hydroxide gel,magnesium trisilicate)
Normalized name: aluminum hydroxide / magnesium trisilicate
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00686699
Drug: Preladenant
Normalized name: Preladenant
DrugBank: Preladenant (DB11864)
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsules
Study: NCT00736385
Drug: Glucophage (Metformin)
Normalized name: metformin Oral Tablet [Glucophage]
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: metformin XR 2000 mg daily for 12 months
Study: NCT01637246
Drug: Any Fixed Combination Therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with POAG or OHT previously treated with monotherapy and currently treated with any fixed combination therapy. This was a retrospective chart review study, so no treatment was administered in this study.
Study: NCT01231802
Drug: Eniluracil
Normalized name: Eniluracil
DrugBank: Eniluracil (DB03516)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eniluracil (40 mg) orally at 18:00 ± 1 hour (6:00 PM) on Days 1, 8, \& 15
Study: NCT01231802
Drug: 5-Fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU (30 mg/m2) orally at 7:00 AM ± 1 hour on Days 2, 9, \& 16
Study: NCT02411994
Drug: Pyronaridine-artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02150785
Drug: Streptokinase
Normalized name: Streptokinase
DrugBank: Streptokinase (DB00086)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02030457
Drug: Beclomethasone dipropionate BAI
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breath Activated Inhaler (BAI)
Study: NCT02030457
Drug: Beclomethasone dipropionate MDI
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metered Dose Inhaler (MDI)
Study: NCT04065295
Drug: BI 1356225
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Dose
Study: NCT03020797
Drug: Perampanel
Normalized name: Perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02283242
Drug: Galantamine
Normalized name: Galantamine
DrugBank: Galantamine (DB00674)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral use for 12 weeks
Study: NCT02110563
Drug: DCR-MYC
Normalized name: DCR-PHXC free acid
DrugBank: Nedosiran (DB17635)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosing: 2 hour IV infusion on Day 1 and 8 of each 21 day cycle.~Starting dose: 0.1mg/kg/dose~Dose escalation: 100%, 50%, or 25% increase in subsequent cohorts depending upon toxicity.~Number of cycles: until progression or unacceptable toxicity develops.
Study: NCT00466986
Drug: Abraxane
Normalized name: Abraxane
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Carboplatin day1 every 28days. Abraxane day1,8,15 every 28days
Study: NCT00561067
Drug: Erythropoietin
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPO 500 IU/kg diluted in 50 ml saline and infused in 30 minutes; treatment is started within eight hours after the spinal injury; the same drug dosage will be infused at 24 and 48 hours
Study: NCT00561067
Drug: Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MP 30 mg/kg intravenous (iv) in the first hour, followed by 5.4 mg/kg/h for 23 hours if treatment is started within three hours after the spinal injury,or for 48 hours if treatment is started between three and eight hours (protocol NASCIS III, National Acute Spinal Cord Injury Study)
Study: NCT00504452
Drug: KP-1461
Normalized name: KP-1461
DrugBank: KP-1461 (DB05644)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dosage, 1600 mg bid for 124 days
Study: NCT03198585
Drug: Empagliflozin 10 MG
Normalized name: empagliflozin 10 MG
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Capsule, once a day for 90 days
Study: NCT00886756
Drug: AZD8529
Normalized name: AZD8529
DrugBank: AZD8529 (DB16073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT01486992
Drug: mFOLFIRI+Nimotuzumab
DrugBank: Nimotuzumab (DB06192)
Approvals — FDA: no, EMA: no, PMDA: no
Description: irinotecan 180mg/m2，iv ，d1，LV 200 mg/m2 ，2h，d1，5-FU 400 mg/m2， iv，d1 5-FU 2400mg/m2，CIV，46h，q2w Nimotuzumab 200mg，iv，qw
Study: NCT00305773
Drug: vorinostat
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally once daily
Study: NCT04484558
Drug: Actilyse
Normalized name: Actidose
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion
Study: NCT00780234
Drug: PIOGLITAZONE VS. PLACEBO 30 mg
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be randomized to receive either pioglitazone or placebo. Pioglitazone hydrochloride, a thiazolidinedione antidiabetic agent and a potent peroxisome proliferator-~activated receptor-gamma agonist. It is FDA approved for the treatment of Type II diabetes. It has been previously administered to non-diabetic subjects. The most common side effect of pioglitazone is fluid retention and modest weight gain. There is a potential risk that pioglitazone may cause an elevation in liver enzymes and more serious hepatotoxicity (rare). There is risk of edema and weight gain associated with pioglitazone therapy. 5% experienced peripheral edema in clinical trials. fluid retention may result in new onset heart failure or exacerbation of existing heart failure. Small risk of hypoglycemia, anemia, myalgia, bone fracture, headache, and macular retinal edema exists. There is insufficient information to confirm its safety in Pregnancy/Breastfeeding. Bladder cancer is more serious but rare.
Study: NCT01296334
Drug: morphine LO
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous infusion, 10 mg, once, 4 hours
Study: NCT01296334
Drug: Morphine Hi
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous infusion, 20 mg, once, 4 hours
Study: NCT01296334
Drug: Buprenorphine LO
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: intravenous infusion, 0.3 mg, once, 4 hours
Study: NCT01296334
Drug: Buprenorphine Hi
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: intravenous infusion, 0.6 mg, once, 4 hours
Study: NCT00305773
Drug: vorinostat
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally three times daily
Study: NCT04097925
Drug: Doravirine
Normalized name: Doravirine
DrugBank: Doravirine (DB12301)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Doravirine 100 mg tablet
Study: NCT04097925
Drug: Descovy
Normalized name: Descovy
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tenofovir alafenamide 25 mg / emtricitabine 200 mg tablet
Study: NCT00073541
Drug: EMD 72000
Normalized name: Emdisterone
DrugBank: Drostanolone propionate (DB14655)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01064518
Drug: Botulinum Toxin Type A
Normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: RT001 (Botulinum Toxin Type A Topical Gel, Dose A) applied topically at Baseline (Day 0) to the lateral canthal lines
Study: NCT01192581
Drug: hydroxyethyl starch 130/0.4 and sodium chloride injection
DrugBank: Hydroxyethyl Starch (DB09106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: routine treatment for brain hypoperfusion plus hydroxyethyl starch 130/0.4 and sodium chloride injection 500mg
Study: NCT01192581
Drug: hydroxyethyl starch 130/0.4 and sodium chloride injection
DrugBank: Hydroxyethyl Starch (DB09106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: routine treatment for brain hypoperfusion plus hydroxyethyl starch 130/0.4 and sodium chloride injection 1000mg
Study: NCT01192581
Drug: hydroxyethyl starch 130/0.4 and sodium chloride injection
DrugBank: Hydroxyethyl Starch (DB09106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: routine treatment for brain hypoperfusion plus hydroxyethyl starch 130/0.4 and sodium chloride injection 1500mg
Study: NCT01603758
Drug: Ezetimibe
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ezetimibe 10 mg/day or placebo will be given for 6 weeks
Study: NCT00301652
Drug: mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MMF,1.0g/d
Study: NCT03601091
Drug: DORMICUM 5MG/5 ML
Normalized name: Doronicum Mexicanum Flower
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Infusion therapy of the drug
Study: NCT04313205
Drug: JKB-122 in capsule or tablet form
Normalized name: edaravone
DrugBank: Edaravone (DB12243)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: JKB-122 is a TLR4 antagonist and will be administrated in capsule or tablet form
Study: NCT00761189
Drug: Paliperidone
Normalized name: Paliperidone
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Paliperidone extended-release (ER) tablet will be administered orally in dose range of 3 to 12 milligram (mg) per day for 12 weeks as per Investigator's discretion.
Study: NCT01871675
Drug: IPI-145
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01871675
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01871675
Drug: Bendamustine
Normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03988842
Drug: Alteplase
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lyophilized powder for reconstitution in 50mg vials
Study: NCT03988842
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heparin sodium in 0.45% sodium chloride injection for intravenous use
Study: NCT03988842
Drug: Apixaban
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Apixaban tablet
Study: NCT01837927
Drug: Tiotropium Respimat®
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily for 52 weeks
Study: NCT02891915
Drug: Amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin is an aminopenicillin antibiotic
Study: NCT02891915
Drug: Amoxicillin-clavulanate
Normalized name: amoxicillin-clavulanate
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A fixed-ratio combination of amoxicillin trihydrate, an aminopenicillin, and potassium clavulanate, a beta-lactamase inhibitor, used to treat a broad-spectrum of bacterial infections, especially resistant strains.
Study: NCT02891915
Drug: Cefdinir
Normalized name: Cefdinir
DrugBank: Cefdinir (DB00535)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefdinir is a cephalosporin antibiotic used to treat bacterial infections in many different parts of the body.
Study: NCT01227265
Drug: Preladenant
Normalized name: Preladenant
DrugBank: Preladenant (DB11864)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preladenant 2 mg or 5 mg oral tablet taken twice daily
Study: NCT04005287
Drug: WST-057 (4% pirenzepine) Lose Dose 2mL
Normalized name: pirenzepine
DrugBank: Pirenzepine (DB00670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Solution
Study: NCT04005287
Drug: WST-057 (4% pirenzepine) High Dose 4mL
Normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Solution
Study: NCT01213394
Drug: mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Introduction of CellCept or increase in the dose of CellCept to a maximum of 2 g/day. In patients not already receiving CellCept, azathioprine (AZA), enteric-coated mycophenolate sodium (EC-MPS) or sirolimus (SRL) will be discontinued and replaced by CellCept in divided doses to a maximum of 2 g/day. CNI doses will be reduced to conform to the target trough levels in the low-dose CNI arms of the ELITE-Symphony study +/- steroid dose reduction. Any CNI dose change will require measurement of CNI trough levels at 7 days post dose change +/- 3 days.~Target CNI trough levels in the Symphony study:~* Low-dose CsA: Initial oral dose of 1-2 mg/kg bid, to achieve a target trough level of 50-100 ng/mL.~* Low-dose TAC: Initial oral dose of 0.1 mg/kg/day divided into two doses\* with a target trough level of 3-7 ng/mL (\*Advagraf may also be used at a dose of 0.1 mg/kg once daily with a target trough level of 3-7 ng/mL)
Study: NCT03285802
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letrozole 2.5mg will be taken daily q 30 days
Study: NCT03285802
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus 10mg daily q 28 days